Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

doi:10.1111/J.1471-4159.2007.04777.X

Paper

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

Published Oct 1, 2007 · O. Bar-Am, T. Amit, M. Youdim

Journal of Neurochemistry

Q1 SJR score

78

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

The anti‐Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US Food and Drug Administration, has been shown to possess neuroprotective‐neurorescue activities in in vitro and in vivo models. Recent preliminary studies indicated the potential neuroprotective effect of the major metabolite of rasagiline, 1‐(R)‐aminoindan. In the current study, the neuroprotective properties of 1‐(R)‐aminoindan were assessed employing a cytotoxic model of human neuroblastoma SK‐N‐SH cells in high‐density culture‐induced neuronal death. We show that aminoindan (0.1–1 μmol/L) significantly reduced the apoptosis‐associated phosphorylated protein, H2A.X (Ser139), decreased the cleavage of caspase 9 and caspase 3, while increasing the anti‐apoptotic proteins, Bcl‐2 and Bcl‐xl. Protein kinase C (PKC) inhibitor, GF109203X, prevented the neuroprotection, indicating the involvement of PKC in aminoindan‐induced cell survival. Aminoindan markedly elevated pPKC(pan) and specifically that of the pro‐survival PKC isoform, PKCε. Additionally, hydroxyaminoindan, a metabolite of a novel bifunctional drug, ladostigil [(N‐propargyl‐(3R) aminoindan‐5yl)‐ethyl methyl carbamate], combining cholinesterase and monoamine oxidase inhibitor activity, exerted similar neuroprotective properties. Aminoindan and hydroxyaminoindan also protected rat pheochromacytoma PC‐12 cells against the neurotoxin, 6‐hydroxydopamine. Our findings suggest that both metabolites may contribute to the overall neuroprotective activity of their respective parent compounds, further implicating rasagiline and ladostigil as potentially valuable drugs for treatment of a wide variety of neurodegenerative disorders of aging.

In Vitro Study

Highly Cited

Study Snapshot

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, show potential neuroprotective properties, suggesting their potential as valuable drugs for treating various neurodegenerative disorders of aging.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

Sign up to use Study Snapshot

References

Ladostigil prevents gliosis, oxidative–nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats

Ladostigil prevents glial activation and oxidative-nitrative stress in brain areas linked to memory deficits in Alzheimer's disease rats.

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.

Rasagiline mesylate is a selective MAO-B inhibitor with limited role in Parkinson's disease, but its neuroprotective effects may be of greater interest in various neurodegenerative disorders of aging.

A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo‐APP translation and processing

Ladostigil (TV3326) shows potential as a neuroprotective drug for Alzheimer's and Parkinson's diseases by regulating holo-APP translation and processing.

A(1) adenosine receptor signal and AMPK involving caspase-9/-3 activation are responsible for adenosine-induced RCR-1 astrocytoma cell death.

Adenosine-induced RCR-1 astrocytoma cell death involves caspase-9 and caspase-3 activation, mainly through adenosine receptor signaling and AMPK, with potential for apoptosis and mitochondrial damage.

6-Hydroxydopamine-induced Apoptosis Is Mediated via Extracellular Auto-oxidation and Caspase 3-dependent Activation of Protein Kinase Cδ*

6-hydroxydopamine neurotoxicity is initiated by extracellular auto-oxidation and oxidative stress, with caspase 3-dependent activation of protein kinase C playing a key role in cell death.

Citations

Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism

Monoamine oxidase inhibitors show antiparkinsonian activity in various toxic models of Parkinson's disease, potentially leading to the development of novel therapeutics targeting multiple targets.

Computational design of rasagiline derivatives: Searching for enhanced antioxidant capability

Three promising rasagiline derivatives were identified, showing potential as oral drugs and antioxidants for treating neurodegenerative disorders.

Preventative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline derivatives (N-functional group loading) on MPTP-induced parkinsonism in mice.

1-Me-N-propargyl-TIQ effectively prevents Parkinson's disease-like signs in mice, while other N-functional groups show distinct pharmacological properties.

N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease.

N-propargylamine-hydroxypyridinone hybrids show promising potential as multitargeted ligands for Alzheimer's disease therapy, with excellent iron-chelating activity and potent monoamine oxidase B inhibitory effects.

Bioinspired design for the assembly of Glypromate® neuropeptide conjugates with active pharmaceutical ingredients

This study developed a bioinspired methodology for creating novel CNS multitarget drugs by conjugating Glypromate® neuropeptide with active pharmaceutical ingredients, offering increased systemic resistance and controlled release within the CNS.

Dopaminergic stimulants and risk of Parkinson's disease

Sustained dopaminergic stimulant use is associated with lower Parkinson's incidence in seniors with ADHD, supporting a re-examination of certain dopaminergics as potential disease-modifying agents.

6-Hydroxydopamine: a far from simple neurotoxin

6-Hydroxydopamine (6-OHDA) is a neurotoxin that selectively destroys catecholaminergic nerves in sympathetically innervated tissues, and its toxic products contribute to its observed effects in Parkinson's disease models.

A phenolic amide (LyA) isolated from the fruits of Lycium barbarum protects against cerebral ischemia–reperfusion injury via PKCε/Nrf2/HO-1 pathway

Lyciumamide A (LyA) protects against cerebral ischemia-reperfusion injury by improving antioxidant activity and reducing oxidative damage, partly through activation of the PKC/Nrf2/HO-1 pathway.